Press Releases - Immunology

Press Releases - Immunology

July 20, 2020
Findings from newly published research demonstrate promise of ultra-sensitive biomarker technology to identify and define high-risk populations through quantification of interferon (IFN) type I
May 11, 2020
Test deployed on Quanterix' Ultrasensitive Simoa® platform improves sensitivity and specificity for measuring immune response and seroconversion earlier and with higher resolution
April 24, 2020
Grants will award researchers seeking to harness biomarkers to improve diagnosis, prognosis or treatment efficacy studies with access to Quanterix’ ultra-sensitive detection solutions
January 10, 2019
Following successful beta program, the Simoa SP-X next generation benchtop and CorPlex are launching ahead of schedule to further revolutionize cancer research, immunotherapy monitoring, and drug development
CAMBRIDGE, MA – August 19, 2011 – Quanterix Corporation, a company enabling a new generation of molecular diagnostic tests based on its revolutionary Single Molecule Array (SiMoA™) technology, today announced results of a pilot study to measure biomarkers of inflammation from patients with Crohn’s…
CAMBRIDGE, MA – November 2, 2010 – Quanterix Corporation, a single molecule technology company focused on developing a next generation diagnostics platform, announced today that it was awarded a total of $733,437 in grants under the Qualifying Therapeutic Discovery Project (QTDP) program. The QTDP…

This website uses cookies. By continuing to use this website you are acknowledging and agree with our cookie policy.

AgreeLearn more